orelabrutinib
Generic: Bruton's Tyrosine Kinase inhibitor·Code: ZB020
orelabrutinib: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Zenas BioPharma, Inc. (ZBIO) | Phase 3 |
Clinical Trials (1)
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis
Frequently asked questions
Who is developing orelabrutinib?
orelabrutinib is being developed by Zenas BioPharma, Inc..
How many clinical trials involve orelabrutinib?
BioSniper tracks 1 clinical trial involving orelabrutinib.
Get deeper analysis on orelabrutinib
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis